A company has entered into a non-clinical evaluation agreement with NIAID, partnering with AFRRI on protocol design that meets FDA Animal Rule criteria.
3 reports, 2 independent
Updated Aug 12
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A company has entered into a non-clinical evaluation agreement with NIAID, partnering with AFRRI on protocol design that meets FDA Animal Rule criteria.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- NIAID funded a study at AFRRI to evaluate the therapeutic efficacy of a company's product.Sub-event
Company partners with NIAID and AFRRI on protocol design reviewed by FDA.1 source
Keep exploring
The entities involved
-
National Institute of Allergy and Infectious Diseases
US research institute for the treatment and prevention of infectious diseases
Nothing else this week.
-
Armed Forces Radiobiology Research Institute
joint American military radiobiology research institution
Nothing else this week.
- FDA
-
company
legal entity representing an association of people, whether natural, legal or a mixture of both, with a specific objective